LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive mHealth Innovation

SAN JOSE, Calif.--(BUSINESS WIRE)--LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO), the leading provider of cloud-based solutions for clinical research. LifeMap is joining Medidata’s AppConnect Partner Program in support of mobile health (mHealth) innovation.

“Through our AppConnect Partner Program, we are building an ecosystem of world-class developers with powerful mobile capabilities to support innovation and patient engagement in clinical trials”

As a certified and inaugural AppConnect Partner, LifeMap Solutions will leverage its extensive experience developing patient engagement tools to build consumer-friendly mobile apps and remote patient-research programs for clinical trials. These apps will collect data from patients and upload it directly into the regulatory-compliant, secure environment of the Medidata Clinical Cloud^TM, making it easier for Medidata’s clients to bring mHealth tools into the highly structured clinical trials environment.

“Medidata’s advanced technology has significantly impacted clinical trials by making the process more efficient and productive, much like how ResearchKit apps have impacted research studies,” said Corey Bridges, CEO of LifeMap Solutions. “Through this partnership, we’re expanding the scope of our professional mHealth app development services. As the first commercial developer on ResearchKit and one of the inaugural AppConnect Partners, we’re excited to bring our skills to bear in the realm of clinical trials.”

The AppConnect Partner Program will be unveiled at Medidata Symposium, which runs from October 17-19, 2016, in Phoenix, Arizona. Medidata’s annual conference brings together leaders from across the life sciences to share innovative ideas and best practices for the effective design, planning, execution, management and reporting of clinical studies using the Medidata platform.

LifeMap Solutions will unveil Brewed Awakening, its mock clinical trial app, at Medidata Symposium. Brewed Awakening studies the effects of caffeine consumption on spatial memory. The mock app aims to demonstrate the power and benefits of combining LifeMap’s digital health expertise with Medidata’s powerful cloud platform. A demo of the app will feature a short consent process for data collection, followed by a series of tests and surveys that measure spatial memory before and after caffeine consumption -- or with no caffeine consumption at all. Dr. Steve Hershman, Principal Scientist of LifeMap Solutions, will also participate in a panel session on trends in, and best practices for, developing clinical research apps and mHealth solutions.

“Through our AppConnect Partner Program, we are building an ecosystem of world-class developers with powerful mobile capabilities to support innovation and patient engagement in clinical trials,” said Kara Dennis, Medidata’s managing director of mHealth. “LifeMap has extensive experience building engaging, consumer-friendly apps on ResearchKit for leading academic research centers. We’re thrilled to partner with them and help our joint clients adopt mobile health tools that have the potential to increase the efficiency of their clinical development programs, improve the experience for patients and speed up the delivery of vital new therapies.”

About LifeMap Solutions

LifeMap Solutions develops innovative digital health solutions with world-class medical, research, and commercial institutions. From apps for research and clinical care to EMR-supporting middleware and an app development platform, LifeMap’s products empower users to better understand and manage their health and researchers and care providers to reach and serve larger audiences. LifeMap Solutions is a subsidiary of BioTime, Inc., and is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

About Medidata Patient Cloud

Medidata Patient Cloud^® is a comprehensive and regulatory-compliant mobile health solution that accelerates patient-centric clinical research. Patient Cloud enables sponsors to use sensors and apps that capture a richer, more complete dataset directly from the patient, improving the clinical trial experience on the Medidata Clinical Cloud. The suite of solutions includes Sensor Link, a data ingestion platform for biosensors and wearables; AppConnect, an SDK built to integrate apps within the Medidata Clinical Cloud; and ePRo, a mobile app that collects responses to patient questionnaires and diaries.

About Medidata

Medidata is reinventing global drug development by creating the industry’s leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including more than 700 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud^® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world’s top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.